Breaking News Instant updates and real-time market news.

AET

Aetna

$199.94

-0.97 (-0.48%)

, CVS

CVS Health

$73.81

-0.68 (-0.91%)

14:25
10/15/18
10/15
14:25
10/15/18
14:25

Cowen pharmaceuticals analyst to hold an analyst/industry conference call

Healthcare Analysts, along with Cowen's Washington Research Group and a former Senior Deputy General Counsel at a major California insurer and the former Chief Litigator at the California Department of Managed Health, discuss the mergers of Aetna/CVS and Express Scripts/Cigna on an Analyst/Industry conference call to be held on October 15 at 3 pm.

AET

Aetna

$199.94

-0.97 (-0.48%)

CVS

CVS Health

$73.81

-0.68 (-0.91%)

ESRX

Express Scripts

$94.53

0.24 (0.25%)

CI

Cigna

$206.28

-0.77 (-0.37%)

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 01

    Nov

AET Aetna
$199.94

-0.97 (-0.48%)

08/27/18
RBCM
08/27/18
NO CHANGE
Target $94
RBCM
Outperform
Express Scripts price target raised to $94 from $90 at RBC Capital
RBC Capital analyst George Hills raised his price target on Express Scripts (ESRX) to $94 and kept his Outperform rating, citing the shareholders' "blessing" of the merger with Cigna (CI). The analyst notes that even though the regulators are yet to rule on the deal, he expects the merger to close by the end of the year and has a positive view of the "vertical consolidation thesis" for the company. Hill adds that the chance of a Department of Justice challenge to the merger is small in light of the seemingly clear path of the CVS (CVS) - Aetna (AET) merger, but if regulators do seek concessions, he expects the necessary divestitures to be small.
09/10/18
SDLR
09/10/18
INITIATION
Target $60
SDLR
Buy
Hartford Financial initiated with a Buy at Sandler ONeill
Sandler ONeill analyst Paul Newsome initiated Hartford Financial (HIG) with a Buy rating and $60 price target, citing his view that its valuation is "relatively attractive" and that the biggest near-term risk for investors has been resolved by the purchase of The Navigators Group (NAVG), which he sees having several benefits. Newsome also believes the recent acquisition of Aetna's (AET) benefits business will be a relatively strong earnings growth opportunity, he tells investors.
09/17/18
RBCM
09/17/18
NO CHANGE
Target $101
RBCM
Outperform
CVS Health price target raised to $101 from $90 at RBC Capital
RBC Capital analyst George Hill raised his price target on CVS Health (CVS) to $101 and kept his Outperform rating, citing the increased visibility of the company's merger with Aetna (AET) after its recent comments that it expects the deal to close in early Q4. The analyst also points to "de-risked" CVS investment thesis as it pertains to pharmacy benefit managers rebates and the much higher relative multiples for managed care companies, even though he warns that investors may still be spooked by any potential steps that the White House takes to drive prescription drug prices lower. Hill notes however that the latest government funding bill pulled the text that required drug companies to disclose prices in their ads, implying that the political will to change status quo may be limited.
10/02/18
LEER
10/02/18
NO CHANGE
LEER
Outperform
Intersect ENT's Sinuva reimbursement policies 'steps in right direction,' says Leerink
Leerink analyst Richard Newitter reiterates an Outperform rating on Intersect ENT following some positive progress on the reimbursement front for Sinuva in the last several weeks, namely Aetna (AET) covering Sinuva and Anthem (ATNM) adding it to its formulary this past week. The analyst believes these positive coverage policies represent steps in the right direction to a potentially quicker and more consistent reimbursement process using the specialty pharmacy channel, an area where the company has faced some challenges.
CVS CVS Health
$73.81

-0.68 (-0.91%)

09/20/18
LEER
09/20/18
NO CHANGE
Target $250
LEER
Outperform
Cigna price target raised to $250 from $235 at Leerink
Leerink analyst Ana Gupte raised her price target on Outperform-rated Cigna (CI) to $250 from $235 following meetings with a panel of PBM and Specialty Rx specialists, which increased her bullishness on Cigna and Market Perform-rated Express Scripts (ESRX). In a research note to investors, Gupte says she also came away with raised confidence on the achiveability of the $4B annual drug cost savings from the Express Scripts switch by Anthem (ANTM) to IngenioRx in partnership with CVS (CVS). She adds that smaller independent PBMs still have niche opportunities with smaller regional third-party health plans, noting that Magellan Health (MGLN) is well positioned in this market, though loss of substantial business in Florida Seriously Mentally Ill is a headwind in Rx as well.
08/23/18
08/23/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. ROSENBLATT BOOSTS AMD PRICE TARGET TO STREET HIGH: Rosenblatt analyst Hans Mosesmann raised his price target for AMD (AMD) shares to $30 from $27. Mosesmann's new price target represents the high among Wall Street sell-side analysts. Following the meetings, Mosesmann has renewed conviction in AMD's multi-year double digit growth profile. Further, he's impressed by the analysis investors are doing in the name after years of disregard. AMD is up 4.1% in late morning trading. CANTOR CUTS AETNA TO NEUTRAL: Cantor Fitzgerald analyst Steven Halper downgraded Aetna (AET) to Neutral from Overweight with a price target of $202. The stock now trades at just a 4.6% discount to the implied CVS Health (CVS) acquisition value of about $207 per share, Halper said. He believes the narrowed deal spread reflects an increased likelihood of regulatory approval. Halper cites limited potential upside for his downgrade of Aetna to Neutral. NIELSEN UPGRADED TO NEUTRAL AT GOLDMAN: Goldman Sachs analyst George Tong upgraded Nielsen Holdings (NLSN) to Neutral and raised his price target for the shares to $25 from $20. With activist Elliott Management pushing for a sale and increased deal activity in the Information Services sector, Tong sees increased likelihood of Nielsen being involved in a transaction. His upgrade to Neutral and price target increase come after the analyst incorporated a potential takeover into his model. Nielsen is up 3.3% in late morning trading. IMPERIAL SEES SUBSCRIBER UPSIDE FOR NETFLIX: Imperial Capital analyst David Miller believes Netflix's (NFLX) experiment with ending billing through Apple's (AAPL) app store in 33 countries outside the U.S. likely implies upside to its Q3 international subscriber guidance. The analyst said he has a tough time believing that Netflix would "experiment" with billing infrastructure mid-quarter if it did not believe that its international subscriber levels were trending ahead of guidance. As such, Miller raised his Q3 international subscriber estimate to 4.46M from 4.35M. He kept an Outperform rating on Netflix with a $494 price target. TARGET GETS UPGRADE AND DOWNGRADE: Target (TGT) was upgraded to Outperform from Market Perform at Telsey Advisory, and downgraded to Peer Perform from Outperform at Wolfe Research.
ESRX Express Scripts
$94.53

0.24 (0.25%)

10/03/18
LEER
10/03/18
NO CHANGE
LEER
Upcoming midterm elections to act as key catalyst driving healthcare, says Leerink
Leerink analyst Ana Gupte expects the upcoming midterm elections to act as a key catalyst driving healthcare. This midterm has the potential for even more impact given the 2020 Presidential election could even lead to a Democratic supermajority, she contends. Gupte sees the most upside opportunity in Managed Medicaid stocks, such as Centene (CNC) and Molina Healthcare (MOH), and for Facilities names like HCA Healthcare (HCA) with a Blue Wave increasing Red state Medicaid expansions. Medicare Advantage with Humana (HUM) as the flagship name is her contrarian election pick. The analyst recommends buying Diversified MCOs with captive PBMs like UnitedHealth (UNH)/Optum [OP], Anthem (ANTM)/Ingenio Rx, and Cigna (CI)/Express Scripts (ESRX) under all scenarios.
09/26/18
CANT
09/26/18
INITIATION
Target $245
CANT
Overweight
Cigna initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper started Cigna (CI) with an Overweight rating and $245 price target. The analyst believes the company's acquisition of Express Scripts (ESRX), which should close by year-end 2018, is a "logical fit, both strategically and financially, with natural synergies." He views Cigna's risk/reward as attractive at current levels.
09/27/18
RHCO
09/27/18
NO CHANGE
Target $260
RHCO
Buy
Cigna price target raised to $260 from $244 at SunTrust
SunTrust analyst David MacDonald raised his price target on Cigna (CI) and kept his Buy rating to reflect the benefits of its combination with Express Scripts (ESRX). The analyst cites the "virtues of the deal" coming from the "combined pharmacy/medical, clinical horsepower, and attractive synergies", adding that he sees the benefits of the combination as "underappreciated" by the market. MacDonald expects the Cigna-Express Scripts entity to have a "big 2019 and beyond", adding the their "robust" expected free cash flows will allow them some "financial flexibility". The analyst also sees Cigna's 13-times expected FY19 earnings multiple as "compelling".
10/03/18
GSCO
10/03/18
UPGRADE
Target $250
GSCO
Conviction Buy
Cigna upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Stephen Tanal added Buy-rated Cigna (CI) to his firm's Conviction List and raised his price target for the shares to $250 from $227. After revisiting the company's fundamental story, the analyst continues to believe Cigna is well positioned to take share of the U.S. commercial market. He believes fundamentals support a higher standalone multiple. Further, while not taking a view on the Express Scripts (ESRX) deal closing, Tanal believes the combined company could reach its targeted leverage ratio earlier than expected.
CI Cigna
$206.28

-0.77 (-0.37%)

10/12/18
JEFF
10/12/18
DOWNGRADE
JEFF
Hold
Molina Healthcare downgraded to Hold on valuation at Jefferies
Jefferies analyst David Windley downgraded Molina Healthcare (MOH) to Hold with an unchanged price target of $152. The downgrade is based mostly on valuation as the company has pulled forward "significant earnings power faster than expected" and appreciated 80% year-to-date, Windley tells investors in a research note. The analyst, however, remains constructive on Managed Care fundamentals with a bias to own diversified insurers. He likes we like UnitedHealth's (UNH) Q4 set-up and also believe Cigna's (CI) multiple can expand.
10/03/18
10/03/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. HSBC CUTS NIKE TO HOLD: HSBC analyst Erwan Rambourg downgraded Nike (NKE) to Hold from Buy and kept his $92 price target on shares. The analyst noted that while the company's Q1 results were strong and the outlook "remains rock solid", the company's valuation multiple of 30-times forward earnings may weigh on the stock. EVERCORE CUTS ORACLE TO IN LINE: Evercore ISI analyst Kirk Materne downgraded Oracle (ORCL) to In Line from Outperform with a price target of $53 to reflect the update of his model into FY20. The analyst noted that even though growth is expected to accelerate modestly in the second half of this year, there are not enough catalysts for share to "meaningfully re-rate" from current levels, adding that the risk-reward appears balanced following this summer's rally. CIGNA BOOSTED TO CONVICTION BUY AT GOLDMAN: Goldman Sachs analyst Stephen Tanal added Buy-rated Cigna (CI) to his firm's Conviction List and raised his price target for the shares to $250 from $227. After revisiting the company's fundamental story, the analyst continues to believe Cigna is well positioned to take share of the U.S. commercial market. He believes fundamentals support a higher standalone multiple. CREDIT SUISSE DOWNGRADES HI-CRUSH, COVIA: Credit Suisse analyst Jim Wicklund downgraded Hi-Crush Partners (HCLP) to Neutral from Outperform and Covia (CVIA) to Underperform from Neutral. The analyst noted that the weakness that has rippled through the frack sand subsector since August came sooner than he expected. The ferocity of price competition, based on commentary from the sand companies in addition to their OFS and E&P customers, is also greater than he had expected, he added. In late morning trading, Hi-Crush was down almost 2%, while Covia was down just over 4%. GOLDMAN RAISES ALIBABA'S PRICE TARGET: Goldman Sachs analyst Piyush Mubayi reiterated a Buy rating on Alibaba (BABA) and raised his price target to $247 from $241. The analyst predicts strong growth in the cloud computing and financial businesses for the company, and expects Alibaba to continue to invest for future growth on "multiple fronts," including retailing, digital advertising and entertainment, which he believes will be a total addressable market of about RMB80T by the end of 2020.

TODAY'S FREE FLY STORIES

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

, INCY

Incyte

$66.09

1.66 (2.58%)

18:44
10/21/18
10/21
18:44
10/21/18
18:44
Hot Stocks
Eli Lilly, Incyte shares updated safety analysis of Olumiant in active RA »

Eli Lilly (LLY) and…

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

INCY

Incyte

$66.09

1.66 (2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

WAL

Western Alliance

$49.42

-4.11 (-7.68%)

18:36
10/21/18
10/21
18:36
10/21/18
18:36
Recommendations
Western Alliance analyst commentary  »

Western Alliance should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

FFBC

First Financial Bancorp

$24.91

-2.51 (-9.15%)

18:32
10/21/18
10/21
18:32
10/21/18
18:32
Upgrade
First Financial Bancorp rating change  »

First Financial upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 31

    Oct

HRZN

Horizon Technology

$11.45

0.06 (0.53%)

18:29
10/21/18
10/21
18:29
10/21/18
18:29
Downgrade
Horizon Technology rating change  »

Horizon Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

NCNA

NuCana

$18.90

1.9 (11.18%)

18:25
10/21/18
10/21
18:25
10/21/18
18:25
Recommendations
NuCana analyst commentary  »

NuCana updated Phase Ib…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

CBNK

Capital Bancorp

$12.75

(0.00%)

18:25
10/21/18
10/21
18:25
10/21/18
18:25
Initiation
Capital Bancorp initiated  »

Capital Bancorp initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$13.19

0.005 (0.04%)

, GOLD

Randgold

$81.91

0.23 (0.28%)

18:03
10/21/18
10/21
18:03
10/21/18
18:03
Hot Stocks
ISS recommends Barrick, Randgold shareholders vote in favor of merger »

Barrick Gold (ABX)…

ABX

Barrick Gold

$13.19

0.005 (0.04%)

GOLD

Randgold

$81.91

0.23 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$140.06

0.74 (0.53%)

, IBM

IBM

$129.16

-1.36 (-1.04%)

17:45
10/21/18
10/21
17:45
10/21/18
17:45
Hot Stocks
Visa readies B2B Connect for market »

Visa (V) announced new…

V

Visa

$140.06

0.74 (0.53%)

IBM

IBM

$129.16

-1.36 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 28

    Oct

  • 13

    Nov

  • 13

    Nov

  • 26

    Nov

  • 29

    Jan

  • 03

    Mar

T

AT&T

$32.86

0.36 (1.11%)

, CMCSA

Comcast

$35.97

0.02 (0.06%)

17:42
10/21/18
10/21
17:42
10/21/18
17:42
Hot Stocks
Box Office Battle: 'Halloween' breaks records with scary $77.5M »

Comcast (CMCSA)…

T

AT&T

$32.86

0.36 (1.11%)

CMCSA

Comcast

$35.97

0.02 (0.06%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$55.66

-0.38 (-0.68%)

FOX

21st Century Fox

$45.51

0.05 (0.11%)

FOXA

21st Century Fox

$45.76

-0.05 (-0.11%)

LGF.A

Lionsgate

$22.20

(0.00%)

DIS

Disney

$118.81

2.55 (2.19%)

VIAB

Viacom

$33.24

-0.49 (-1.45%)

VIA

Viacom

$36.75

-0.48 (-1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

  • 12

    Nov

  • 14

    Nov

  • 14

    Nov

FOX

21st Century Fox

$45.51

0.05 (0.11%)

, FOXA

21st Century Fox

$45.76

-0.05 (-0.11%)

17:24
10/21/18
10/21
17:24
10/21/18
17:24
Periodicals
AMC's Collier named next leader of Fox Network, NY Times reports »

Fox (FOXA) will turn to…

FOX

21st Century Fox

$45.51

0.05 (0.11%)

FOXA

21st Century Fox

$45.76

-0.05 (-0.11%)

AMC

AMC Entertainment

$19.81

0.18 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

VLKAY

Volkswagen

$0.00

(0.00%)

17:04
10/21/18
10/21
17:04
10/21/18
17:04
Periodicals
Audi electric SUV facing delay due to software bug, Reuters reports »

Audi's first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BX

Blackstone

$34.66

-0.61 (-1.73%)

17:00
10/21/18
10/21
17:00
10/21/18
17:00
Periodicals
Blackstone to acquire Ulterra for $700M, Reuters reports »

Blackstone has agreed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$15.52

0.035 (0.23%)

, KKR

KKR

$24.22

-0.45 (-1.82%)

16:56
10/21/18
10/21
16:56
10/21/18
16:56
Periodicals
Fiat agrees to sell Magneti Marelli to KKR's Calsonic, Bloomberg says »

Fiat Chrysler (FCAU) has…

FCAU

Fiat Chrysler

$15.52

0.035 (0.23%)

KKR

KKR

$24.22

-0.45 (-1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 30

    Oct

MRK

Merck

$72.34

0.12 (0.17%)

, AZN

AstraZeneca

$39.21

0.25 (0.64%)

16:40
10/21/18
10/21
16:40
10/21/18
16:40
Hot Stocks
Merck, AstraZeneca announce detailed results from Phase 3 SOLO-1 trial »

AstraZeneca (AZN) and…

MRK

Merck

$72.34

0.12 (0.17%)

AZN

AstraZeneca

$39.21

0.25 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

  • 11

    Jan

  • 16

    Feb

VAR

Varian Medical

$104.25

-1.575 (-1.49%)

16:31
10/21/18
10/21
16:31
10/21/18
16:31
Hot Stocks
Varian unveils new Bravos afterloader system for brachytherapy treatments »

Varian announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

14:30
10/21/18
10/21
14:30
10/21/18
14:30
Conference/Events
Neon Therapeutics management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 26

    Oct

  • 07

    Nov

GTHX

G1 Therapeutics

$46.88

-0.07 (-0.15%)

14:13
10/21/18
10/21
14:13
10/21/18
14:13
Hot Stocks
G1 presents additional data from randomized Phase 2 trial in first-line SCLC »

G1 Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

NCNA

NuCana

$18.90

1.9 (11.18%)

14:09
10/21/18
10/21
14:09
10/21/18
14:09
Hot Stocks
NuCana reports additional data on NUC-1031 in advanced biliary tract cancer »

NuCana announced combined…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

, MRK

Merck

$72.34

0.12 (0.17%)

14:05
10/21/18
10/21
14:05
10/21/18
14:05
Hot Stocks
Leap Therapeutics presents esophagogastric cancer data »

Leap Therapeutics (LPTX)…

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

INCY

Incyte

$66.09

1.66 (2.58%)

14:02
10/21/18
10/21
14:02
10/21/18
14:02
Hot Stocks
Incyte announces positive interim data from Phase 2 trial of Pemigatinib »

Incyte announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:58
10/21/18
10/21
13:58
10/21/18
13:58
Hot Stocks
Loxo's larotrectinib delivers 81% ORR in expanded dataset of 109 TRK fusion cancer »

Bayer (BAYRY) and Loxo…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:53
10/21/18
10/21
13:53
10/21/18
13:53
Hot Stocks
Loxo announces larotrectinib clinical update in patients with TRK fusion cancers »

Loxo Oncology (LOXO)…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

13:45
10/21/18
10/21
13:45
10/21/18
13:45
Hot Stocks
Mirati announces updated data from ongoing trial of single agent sitravatinib »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

RHHBY

Roche

$0.00

(0.00%)

13:39
10/21/18
10/21
13:39
10/21/18
13:39
Hot Stocks
Entrectinib shrank tumors in people with NTRK fusion-positive solid tumors »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

GILD

Gilead

$73.27

-0.9 (-1.21%)

, GLPG

Galapagos NV

$107.66

2.29 (2.17%)

13:34
10/21/18
10/21
13:34
10/21/18
13:34
Hot Stocks
Gilead, Galapagos NV announced data from Phase 3 FINCH2 trial of filgotinib »

Gilead Sciences (GILD)…

GILD

Gilead

$73.27

-0.9 (-1.21%)

GLPG

Galapagos NV

$107.66

2.29 (2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 07

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.